Changes in magnetic resonance imaging disease measures over 3 years in mildly disabled patients with relapsing-remitting multiple sclerosis receiving IFN Beata-1a, 22 ore 44 MCG SC TIW, in the cognitive impairment in multiple sclerosis (COGIMUS) study